Compare LTC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | TRVI |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.4B |
| IPO Year | 1994 | 2019 |
| Metric | LTC | TRVI |
|---|---|---|
| Price | $38.38 | $10.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $39.00 | $20.46 |
| AVG Volume (30 Days) | 337.3K | ★ 1.1M |
| Earning Date | 05-04-2026 | 03-17-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | 23.53 | ★ 31.91 |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $262,854,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.24 | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $31.70 | $4.85 |
| 52 Week High | $40.80 | $14.39 |
| Indicator | LTC | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 40.89 |
| Support Level | $34.13 | $10.04 |
| Resistance Level | $40.05 | $11.78 |
| Average True Range (ATR) | 0.71 | 0.78 |
| MACD | -0.17 | -0.19 |
| Stochastic Oscillator | 22.64 | 6.33 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.